A Venditti

Summary

Country: Italy

Publications

  1. ncbi request reprint A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes
    A Venditti
    Hematology, University o Tor Vergata, St Eugenio Hospital, Rome, Italy
    Ann Hematol 79:138-42. 2000
  2. ncbi request reprint Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia
    A Venditti
    Cattedra di Ematologia, Universita di Roma Tor Vergata, Divisione di Ematologia, Rome, Italy
    Blood 96:3948-52. 2000
  3. ncbi request reprint Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation
    A Venditti
    Cattedra di Ematologia, Divisione di Ematologia, Universita di Roma Tor Vergata, Rome, Italy
    Leukemia 17:2178-82. 2003
  4. ncbi request reprint The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia
    F Buccisano
    Department of Biopatologia e Diagnostica per Immagini, Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
    Leukemia 20:1783-9. 2006
  5. ncbi request reprint Minimally differentiated acute myeloid leukaemia (AML-M0): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases
    A Venditti
    Cattedra di Ematologia, Ospedale S Eugenio, Universita di Roma Tor Vergata, Italy
    Br J Haematol 88:784-93. 1994
  6. ncbi request reprint Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group. Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto
    M Montillo
    Divisione di Ematologia, Ospedale Niguarda Ca Granda, Milan, Italy
    Br J Haematol 111:334-7. 2000
  7. ncbi request reprint Quantitative analysis of Fas and bcl-2 expression in hematopoietic precursors
    L Maurillo
    Cattedra di Ematologia, Universita Tor Vergata, Divisione di Ematologia, Ospedale S Eugenio, Piazzale Umanesimo 10, 00144 Rome, Italy
    Haematologica 86:237-43. 2001
  8. ncbi request reprint Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia
    G Del Poeta
    Cattedra di Ematologia, Universita Tor Vergata, Ospedale S Eugenio, P le Umanesimo, 10, 00144 Roma, Italy
    Curr Cancer Drug Targets 8:207-22. 2008
  9. ncbi request reprint O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro
    M Turriziani
    Department of Internal Medicine, University of Rome Tor Vergata, School of Medicine, Via Montpellier 1, Rome, Italy
    Pharmacol Res 53:317-23. 2006
  10. ncbi request reprint Acute megakaryoblastic leukemia: experience of GIMEMA trials
    L Pagano
    Cattedra di Ematologia, Universita Cattolica S Cuore, Roma, Italy
    Leukemia 16:1622-6. 2002

Collaborators

Detail Information

Publications14

  1. ncbi request reprint A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes
    A Venditti
    Hematology, University o Tor Vergata, St Eugenio Hospital, Rome, Italy
    Ann Hematol 79:138-42. 2000
    ..Optimizing this approach might be pursued by selecting, on a biological basis, those cases more likely to respond or by incorporating other differentiating agents or growth factors...
  2. ncbi request reprint Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia
    A Venditti
    Cattedra di Ematologia, Universita di Roma Tor Vergata, Divisione di Ematologia, Rome, Italy
    Blood 96:3948-52. 2000
    ..5 x 10(-4) cells or higher at the end of consolidation strongly predicts relapse and is significantly associated with an MDR1 phenotype and intermediate or unfavorable cytogenetic findings. (Blood. 2000;96:3948-3952)..
  3. ncbi request reprint Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation
    A Venditti
    Cattedra di Ematologia, Divisione di Ematologia, Universita di Roma Tor Vergata, Rome, Italy
    Leukemia 17:2178-82. 2003
    ....
  4. ncbi request reprint The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia
    F Buccisano
    Department of Biopatologia e Diagnostica per Immagini, Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
    Leukemia 20:1783-9. 2006
    ..001, for all comparisons). In conclusion: (1) the threshold of 3.5 x 10(-4) is valid in discriminating risk categories in adult AML and (2) post-Cons MRD assessment is critical to predict disease outcome...
  5. ncbi request reprint Minimally differentiated acute myeloid leukaemia (AML-M0): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases
    A Venditti
    Cattedra di Ematologia, Ospedale S Eugenio, Universita di Roma Tor Vergata, Italy
    Br J Haematol 88:784-93. 1994
    ..No cases of (t9;22), Ph chromosome were observed. Interestingly three out of five patients with faint alpha NBE/alpha ANAE positivity relapsed as typical M4 (one case) or M5a (two cases)...
  6. ncbi request reprint Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group. Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto
    M Montillo
    Divisione di Ematologia, Ospedale Niguarda Ca Granda, Milan, Italy
    Br J Haematol 111:334-7. 2000
    ..Psychosocial problems impaired treatment of some patients on an out-patient basis. Resistant disease, toxicity and logistic problems reduced the number of patients to whom this procedure could actually be applied...
  7. ncbi request reprint Quantitative analysis of Fas and bcl-2 expression in hematopoietic precursors
    L Maurillo
    Cattedra di Ematologia, Universita Tor Vergata, Divisione di Ematologia, Ospedale S Eugenio, Piazzale Umanesimo 10, 00144 Rome, Italy
    Haematologica 86:237-43. 2001
    ..The expression of bcl-2 and Fas was then compared with that of other markers usually associated with immaturity; functional tests using the agonistic antibody anti- Fas CH11 were also carried out...
  8. ncbi request reprint Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia
    G Del Poeta
    Cattedra di Ematologia, Universita Tor Vergata, Ospedale S Eugenio, P le Umanesimo, 10, 00144 Roma, Italy
    Curr Cancer Drug Targets 8:207-22. 2008
    ..The elucidation of the apoptotic machinery and of its defects in AML lays the basis for developing new drugs able to trigger apoptosis and overcome therapy resistance...
  9. ncbi request reprint O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro
    M Turriziani
    Department of Internal Medicine, University of Rome Tor Vergata, School of Medicine, Via Montpellier 1, Rome, Italy
    Pharmacol Res 53:317-23. 2006
    ..In conclusion, these results appear to provide disease-oriented rational basis to design novel clinical protocols for the treatment of acute leukaemia with combined administration of PAT and triazene compounds...
  10. ncbi request reprint Acute megakaryoblastic leukemia: experience of GIMEMA trials
    L Pagano
    Cattedra di Ematologia, Universita Cattolica S Cuore, Roma, Italy
    Leukemia 16:1622-6. 2002
    ..Furthermore, a high number of deaths in CR were observed. On the basis of these data, a specific therapeutic approach, possibly with innovative treatments, should be evaluated...
  11. doi request reprint Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia
    G Del Poeta
    Hematology, Dipartimento di Biomedicina e Prevenzione, Universit à degli Studi di Roma Tor Vergata, Rome, Italy
    Drugs Today (Barc) 52:249-60. 2016
    ....
  12. doi request reprint Mini-extracorporeal circulation minimizes coagulation abnormalities and ameliorates pulmonary outcome in coronary artery bypass grafting surgery
    J Zeitani
    Department of Cardiac Surgery, Tor Vergata University of Rome, Rome, Italy
    Perfusion 28:298-305. 2013
    ..001 for all comparisons). Our study suggests that MECC induces less coagulation disorders, leading to lower postoperative blood loss and better postoperative lung function. This approach may be advantageous in high-risk patients...
  13. ncbi request reprint Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy
    P Niscola
    Leukemia 19:1840-1. 2005
  14. ncbi request reprint Nanomolar level of resveratrol (trans-3,5,4'-trihydroxystilbene) is required, but is not sufficient, to inhibit the growth of human monocytoid tumor cells through an apoptotic-like mechanism
    M M Corsi
    Clinical Pathology Laboratory, Institute of General Pathology, Faculty of Medicine, University of Milan, Milan, Italy
    Drugs Exp Clin Res 28:235-42. 2002
    ..It is also suggested that the synergistic action of other wine components with resveratrol might, at least partially, explain its chemopreventive activity...